Fátima Solange Pasini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Fátima Solange Pasini has a total of 207 co-authors. Here are the top co-authors by number of shared publications:
- Maria Mitzi Brentani
Universidade de São Paulo Faculdade de Medicina Departamento de Radiologia
8 shared publications - Luiz Paulo Kowalski
Head and Neck Surgery Department University of São Paulo Medical School (FMUSP) São Paulo Brazil
7 shared publications - Simone Maistro
Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, ICESP, São Paulo, SP, Brazil
6 shared publications Suely Nonogaki
Department of Pathology, Adolfo Lutz Institute, S�o Paulo, SP 01246‑000, Brazil
6 shared publications- Leandro Luongo Matos
Head and Neck Surgery, Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Universidade de São Paulo (Icesp HCFMUSP). Professor, Surgery, Faculdade Israelita de Ciências da Saúde Albert Einstein, São Paulo, Brazil
5 shared publications - Maria Aparecida Azevedo Koike Folgueira
Faculdade de Medicina Universidade de Sao Paulo, Sao Paulo, Brazil
5 shared publications
Latest Publications
- Open Access
- 9 March 2026
- Published by Springer Nature in Endocrine
- Vol. 91 (1) , 94
MicroRNA signatures associated with radioiodine refractoriness and tumor dedifferentiation in metastatic papillary thyroid carcinoma
Purpose: Radioiodine (RAI) refractoriness and tumor dedifferentiation are major contributors to poor outcomes in metastatic papillary thyroid carcinoma (PTC). microRNAs (miRNAs) are promising biomarkers to identify these aggressive phenotypes. This study aimed to characterize miRNAs expression profiles associated with RAI refractoriness and dedifferentiation. Methods: From a cohort of 108 metastatic PTC patients, 24 cases with available formalin-fixed paraffin-embedded tissue were selected for molecular analysis, including 17 patients who died from disease progression and 7 long-term survivors with stable disease. Total RNA was extracted and analyzed by qPCR. miRNAs with differential expression ( P < 0.10) in univariate analysis were included in multivariate linear regression models. Diagnostic performance was assessed using ROC curve analysis and hierarchical clustering. Results: The cohort had a mean age of 55.2 years and was predominantly male (66.7%). RAI-refractory disease was present in 63.2% of evaluable cases, and dedifferentiation in 33.3%. In multivariate analysis, lower expression of miR-200c-3p was independently associated with RAI refractoriness ( P = 0.005). For tumor dedifferentiation, higher expression of let-7i-5p ( P < 0.001) and miR-19b-3p ( P < 0.001), and lower expression of miR-31-5p ( P = 0.004) and let-7e-5p ( P = 0.036), were independently associated. ROC curve analysis demonstrated high diagnostic accuracy for miR-200c-3p (AUC = 0.929) and let-7i-5p (AUC = 0.958) for, respectively, RAI refractoriness and tumor dedifferentiation. Heatmap analysis revealed clear segregation of phenotypic groups based on miRNA expression. Conclusions: Distinct miRNAs signatures are associated with RAI refractoriness and tumor dedifferentiation in metastatic PTC. These findings support their potential as prognostic biomarkers and may guide future therapeutic stratification.
- 9 March 2026
- Published by Springer Nature in Endocrine
- Vol. 91 (1) , 94
Open AccessMicroRNA signatures associated with radioiodine refractoriness and tumor dedifferentiation in metastatic papillary thyroid carcinoma
Purpose: Radioiodine (RAI) refractoriness and tumor dedifferentiation are major contributors to poor outcomes in metastatic papillary thyroid carcinoma (PTC). microRNAs (miRNAs) are promising biomarkers to identify these aggressive phenotypes. This study aimed to characterize miRNAs expression profiles associated with RAI refractoriness and dedifferentiation. Methods: From a cohort of 108 metastatic PTC patients, 24 cases with available formalin-fixed paraffin-embedded tissue were selected for molecular analysis, including 17 patients who died from disease progression and 7 long-term survivors with stable disease. Total RNA was extracted and analyzed by qPCR. miRNAs with differential expression ( P < 0.10) in univariate analysis were included in multivariate linear regression models. Diagnostic performance was assessed using ROC curve analysis and hierarchical clustering. Results: The cohort had a mean age of 55.2 years and was predominantly male (66.7%). RAI-refractory disease was present in 63.2% of evaluable cases, and dedifferentiation in 33.3%. In multivariate analysis, lower expression of miR-200c-3p was independently associated with RAI refractoriness ( P = 0.005). For tumor dedifferentiation, higher expression of let-7i-5p ( P < 0.001) and miR-19b-3p ( P < 0.001), and lower expression of miR-31-5p ( P = 0.004) and let-7e-5p ( P = 0.036), were independently associated. ROC curve analysis demonstrated high diagnostic accuracy for miR-200c-3p (AUC = 0.929) and let-7i-5p (AUC = 0.958) for, respectively, RAI refractoriness and tumor dedifferentiation. Heatmap analysis revealed clear segregation of phenotypic groups based on miRNA expression. Conclusions: Distinct miRNAs signatures are associated with RAI refractoriness and tumor dedifferentiation in metastatic PTC. These findings support their potential as prognostic biomarkers and may guide future therapeutic stratification.
- Open Access
- 1 January 2026
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 70 (4) , 1-9
MicroRNA expression signatures associated with metastatic progression in papillary thyroid carcinoma
The objective of this study is to compare the miRNA expression profiles of primary tumors and matched metastatic lesions from patients who died due to progression of metastatic PTC. We conducted an exploratory study of patients with PTC who died from disease progression and had tissue samples available from both primary tumors and distant metastases. Total RNA was extracted and analyzed to assess the expression of 64 preselected miRNAs. Expression data were normalized using endogenous controls (let-7g-5p and miR-181a-5p), and differential expression was calculated using the 2-∆Ct method. Those miRNAs detected in < 70% of samples or with cycle threshold (Ct) > 36 were excluded. Univariate analyses were performed using paired tests, and multivariate results were adjusted for multiple comparisons using the Benjamini-Hochberg false discovery rate (FDR) method. Out of 3,555 patients treated for PTC between 1986 and 2015, eight patients were included. Univariate analysis identified five miRNAs differentially expressed in metastatic lesions: let-7e-5p, miR-10b-5p, miR-30e-3p, miR-423-5p, and miR-483-3p. After multivariate adjustment, miR-10b-5p and miR-30e-3p remained independently overexpressed in metastatic tissues. This study is one of the first to demonstrate distinct miRNA expression profiles in metastatic versus primary tumors in fatal PTC cases. The identified miRNAs are known to regulate processes such as cell migration, invasion, and apoptosis in other cancers, suggesting their potential contribution to PTC metastasis.
- 1 January 2026
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 70 (4) , 1-9
Open AccessMicroRNA expression signatures associated with metastatic progression in papillary thyroid carcinoma
The objective of this study is to compare the miRNA expression profiles of primary tumors and matched metastatic lesions from patients who died due to progression of metastatic PTC. We conducted an exploratory study of patients with PTC who died from disease progression and had tissue samples available from both primary tumors and distant metastases. Total RNA was extracted and analyzed to assess the expression of 64 preselected miRNAs. Expression data were normalized using endogenous controls (let-7g-5p and miR-181a-5p), and differential expression was calculated using the 2-∆Ct method. Those miRNAs detected in < 70% of samples or with cycle threshold (Ct) > 36 were excluded. Univariate analyses were performed using paired tests, and multivariate results were adjusted for multiple comparisons using the Benjamini-Hochberg false discovery rate (FDR) method. Out of 3,555 patients treated for PTC between 1986 and 2015, eight patients were included. Univariate analysis identified five miRNAs differentially expressed in metastatic lesions: let-7e-5p, miR-10b-5p, miR-30e-3p, miR-423-5p, and miR-483-3p. After multivariate adjustment, miR-10b-5p and miR-30e-3p remained independently overexpressed in metastatic tissues. This study is one of the first to demonstrate distinct miRNA expression profiles in metastatic versus primary tumors in fatal PTC cases. The identified miRNAs are known to regulate processes such as cell migration, invasion, and apoptosis in other cancers, suggesting their potential contribution to PTC metastasis.
- 11 December 2025
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 231, 113052
Preoperative plasma miR-144-3p to predict persistent type 2 diabetes after gastric bypass – a pilot proof-of-concept study
- 11 December 2025
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 231, 113052
Preoperative plasma miR-144-3p to predict persistent type 2 diabetes after gastric bypass – a pilot proof-of-concept study
- Open Access
Profile of MicroRNAs Associated with Death Due to Disease Progression in Metastatic Papillary Thyroid Carcinoma Patients
Papillary thyroid carcinoma (PTC) is the most common neoplasm of the endocrine system and has an excellent long-term prognosis, with low rates of distant metastatic disease. Although infrequent, there are cases of deaths directly related to PTC, especially in patients with metastatic disease, and the factors that could be associated with this unfavorable outcome remain a major challenge in clinical practice. Recently, research into genetic factors associated with PTC has gained ground, especially mutations in the TERT promoter and BRAF gene. However, the role of microRNAs remains poorly studied, especially in those patients who have an unfavorable outcome at follow-up. This paper aims to evaluate molecular markers related to the different pathological processes of PTC, as well as the histological characteristics of the neoplasm, and to compare this profile with prognosis and death from the disease using an analysis of patients treated for metastatic disease in a single tertiary cancer center. Evaluation of microRNA expression in paraffin-embedded tumor specimens was carried out by quantitative PCR using the TaqMan® Low Density Array (TLDA) system. Metastatic patients who died from progression of PTC had higher expressions of miR-101-3p, miR-17-5p, and miR-191-5p when compared to patients with stable metastatic disease. These findings are of great importance but should be considered as preliminary because of the small sample.
Open AccessProfile of MicroRNAs Associated with Death Due to Disease Progression in Metastatic Papillary Thyroid Carcinoma Patients
Papillary thyroid carcinoma (PTC) is the most common neoplasm of the endocrine system and has an excellent long-term prognosis, with low rates of distant metastatic disease. Although infrequent, there are cases of deaths directly related to PTC, especially in patients with metastatic disease, and the factors that could be associated with this unfavorable outcome remain a major challenge in clinical practice. Recently, research into genetic factors associated with PTC has gained ground, especially mutations in the TERT promoter and BRAF gene. However, the role of microRNAs remains poorly studied, especially in those patients who have an unfavorable outcome at follow-up. This paper aims to evaluate molecular markers related to the different pathological processes of PTC, as well as the histological characteristics of the neoplasm, and to compare this profile with prognosis and death from the disease using an analysis of patients treated for metastatic disease in a single tertiary cancer center. Evaluation of microRNA expression in paraffin-embedded tumor specimens was carried out by quantitative PCR using the TaqMan® Low Density Array (TLDA) system. Metastatic patients who died from progression of PTC had higher expressions of miR-101-3p, miR-17-5p, and miR-191-5p when compared to patients with stable metastatic disease. These findings are of great importance but should be considered as preliminary because of the small sample.
- 8 April 2021
- Published by Wiley in Head & Neck
- Vol. 43 (8) , 2364-2376
MicroRNA‐mediated extracellular matrix remodeling in squamous cell carcinoma of the oral cavity
Background: We evaluated microRNAs and extracellular matrix component profiles in squamous cell carcinoma of the oral cavity (OSCC) in comparison to healthy mucosa.Methods: Retrospective study investigating 64 microRNAs related to oncogenic process and to constituents of the extracellular matrix. We also performed immunohistochemical assays for molecules involved in the same biological processes.Results: High expression of miR‐21‐5p (p < 0.001) and miR‐106‐5p (p < 0.001) and low expression of miR‐320a (p= 0.001) and miR‐222‐3p (p= 0.001) were predictors of malignancy. Individually, miR‐21‐5p exhibited the best statistical performance (area under the curve = 0.972; 95% confidence interval: 0.911–1.000) in the differentiation between tumor tissue and healthy mucosa. Moreover, tumor sample showed increased expression of MMP‐2, MMP‐9, α‐laminin, and β‐laminin in tumor‐related fibroblasts and lower continuity of type IV collagen in the basement membrane.Conclusion: The present study demonstrates the biological effects of microRNAs on the carcinogenesis of OSCC as well as the intense modification of the tumor microenvironment.
- 8 April 2021
- Published by Wiley in Head & Neck
- Vol. 43 (8) , 2364-2376
MicroRNA‐mediated extracellular matrix remodeling in squamous cell carcinoma of the oral cavity
Background: We evaluated microRNAs and extracellular matrix component profiles in squamous cell carcinoma of the oral cavity (OSCC) in comparison to healthy mucosa.Methods: Retrospective study investigating 64 microRNAs related to oncogenic process and to constituents of the extracellular matrix. We also performed immunohistochemical assays for molecules involved in the same biological processes.Results: High expression of miR‐21‐5p (p < 0.001) and miR‐106‐5p (p < 0.001) and low expression of miR‐320a (p= 0.001) and miR‐222‐3p (p= 0.001) were predictors of malignancy. Individually, miR‐21‐5p exhibited the best statistical performance (area under the curve = 0.972; 95% confidence interval: 0.911–1.000) in the differentiation between tumor tissue and healthy mucosa. Moreover, tumor sample showed increased expression of MMP‐2, MMP‐9, α‐laminin, and β‐laminin in tumor‐related fibroblasts and lower continuity of type IV collagen in the basement membrane.Conclusion: The present study demonstrates the biological effects of microRNAs on the carcinogenesis of OSCC as well as the intense modification of the tumor microenvironment.
- Open Access
- 15 December 2020
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 14
Valproic acid combined with cisplatin-based chemoradiation in locally advanced head and neck squamous cell carcinoma patients and associated biomarkers
Background: Cisplatin-based chemoradiation (CCRT) offers locally advanced head and neck squamous cell carcinoma (LAHNSCC) patients high local control rate, however, relapses are frequent. Our goal was to evaluate if association of valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, with CCRT improved response rate (RR) and associated biomarkers. Methods: This phase II trial included patients with unresectable locally advanced (LA) oropharynx (OP) squamous cell carcinoma. CCRT began after 2 weeks of VPA (P1). Primary goal was RR at 8 weeks after chemoradiation (CRT)+VPA (P2). Biomarkers included microRNA (miR) polymerase chain reaction (PCR)-array profiling in plasma compared to healthy controls by two-sample t-test. Distribution of p-values was analysed by beta-uniform mixture. Findings were validated by real-time PCR quantitative polymerase chain reaction (qPCR) for selected miRs in plasma and saliva. p16, HDAC2 and RAD23 Homolog B, Nucleotide Excision Repair Protein (HR23B) tumour immunohistochemistry were evaluated. Results: Given significant toxicities, accrual was interrupted after inclusion of ten LA p16 negative OP patients. All were male, smokers/ex-smokers, aged 41-65 and with previous moderate/high alcohol intake. Nine evaluable patients yielded a RR of 88%. At false discovery rate of 5%, 169 miRs were differentially expressed between patients and controls, including lower expression of tumour suppressors (TSs) such as miR-31, -222, -let-7a/b/e and -145. miR-let-7a/e expression was validated by qPCR using saliva. A HDAC2 H-score above 170 was 90% accurate in predicting 6-month disease-free survival. Conclusions: VPA and CRT offered high RR; however, with prohibitive toxicities, which led to early trial termination. Patients and controls had a distinct pattern of miR expression, mainly with low levels of TS miRs targeting Tumor protein P53 (TP53). miR-let-7a/e levels were lower in patients compared to controls, which reinforces the aggressive nature of such tumours (NCT01695122).
- 15 December 2020
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 14
Open AccessValproic acid combined with cisplatin-based chemoradiation in locally advanced head and neck squamous cell carcinoma patients and associated biomarkers
Background: Cisplatin-based chemoradiation (CCRT) offers locally advanced head and neck squamous cell carcinoma (LAHNSCC) patients high local control rate, however, relapses are frequent. Our goal was to evaluate if association of valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, with CCRT improved response rate (RR) and associated biomarkers. Methods: This phase II trial included patients with unresectable locally advanced (LA) oropharynx (OP) squamous cell carcinoma. CCRT began after 2 weeks of VPA (P1). Primary goal was RR at 8 weeks after chemoradiation (CRT)+VPA (P2). Biomarkers included microRNA (miR) polymerase chain reaction (PCR)-array profiling in plasma compared to healthy controls by two-sample t-test. Distribution of p-values was analysed by beta-uniform mixture. Findings were validated by real-time PCR quantitative polymerase chain reaction (qPCR) for selected miRs in plasma and saliva. p16, HDAC2 and RAD23 Homolog B, Nucleotide Excision Repair Protein (HR23B) tumour immunohistochemistry were evaluated. Results: Given significant toxicities, accrual was interrupted after inclusion of ten LA p16 negative OP patients. All were male, smokers/ex-smokers, aged 41-65 and with previous moderate/high alcohol intake. Nine evaluable patients yielded a RR of 88%. At false discovery rate of 5%, 169 miRs were differentially expressed between patients and controls, including lower expression of tumour suppressors (TSs) such as miR-31, -222, -let-7a/b/e and -145. miR-let-7a/e expression was validated by qPCR using saliva. A HDAC2 H-score above 170 was 90% accurate in predicting 6-month disease-free survival. Conclusions: VPA and CRT offered high RR; however, with prohibitive toxicities, which led to early trial termination. Patients and controls had a distinct pattern of miR expression, mainly with low levels of TS miRs targeting Tumor protein P53 (TP53). miR-let-7a/e levels were lower in patients compared to controls, which reinforces the aggressive nature of such tumours (NCT01695122).
- 1 November 2020
- Published by Elsevier in Oral Oncology
- Vol. 110, 104909
Cancer-associated fibroblast regulation by microRNAs promotes invasion of oral squamous cell carcinoma
- 1 November 2020
- Published by Elsevier in Oral Oncology
- Vol. 110, 104909
Cancer-associated fibroblast regulation by microRNAs promotes invasion of oral squamous cell carcinoma
- Open Access
- 9 October 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-12
Extracellular Vesicles Shedding Promotes Melanoma Growth in Response to Chemotherapy
Extracellular vesicles (EVs) are emerging as key players in intercellular communication. EVs can transfer biological macromolecules to recipient cells, modulating various physiological and pathological processes. It has been shown that tumor cells secrete large amounts of EVs that can be taken up by malignant and stromal cells, dictating tumor progression. In this study, we investigated whether EVs secreted by melanoma cells in response to chemotherapy modulate tumor response to alkylating drugs. Our findings showed that human and murine melanoma cells secrete more EVs after treatment with temozolomide and cisplatin. We observed that EVs shed by melanoma cells after temozolomide treatment modify macrophage phenotype by skewing macrophage activation towards the M2 phenotype through upregulation of M2-marker genes. Moreover, these EVs were able to favor melanoma re-growth in vivo, which was accompanied by an increase in Arginase 1 and IL10 gene expression levels by stromal cells and an increase in genes related to DNA repair, cell survival and stemness in tumor cells. Taken together, this study suggests that EVs shed by tumor cells in response to chemotherapy promote tumor repopulation and treatment failure through cellular reprogramming in melanoma cells.
- 9 October 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-12
Open AccessExtracellular Vesicles Shedding Promotes Melanoma Growth in Response to Chemotherapy
Extracellular vesicles (EVs) are emerging as key players in intercellular communication. EVs can transfer biological macromolecules to recipient cells, modulating various physiological and pathological processes. It has been shown that tumor cells secrete large amounts of EVs that can be taken up by malignant and stromal cells, dictating tumor progression. In this study, we investigated whether EVs secreted by melanoma cells in response to chemotherapy modulate tumor response to alkylating drugs. Our findings showed that human and murine melanoma cells secrete more EVs after treatment with temozolomide and cisplatin. We observed that EVs shed by melanoma cells after temozolomide treatment modify macrophage phenotype by skewing macrophage activation towards the M2 phenotype through upregulation of M2-marker genes. Moreover, these EVs were able to favor melanoma re-growth in vivo, which was accompanied by an increase in Arginase 1 and IL10 gene expression levels by stromal cells and an increase in genes related to DNA repair, cell survival and stemness in tumor cells. Taken together, this study suggests that EVs shed by tumor cells in response to chemotherapy promote tumor repopulation and treatment failure through cellular reprogramming in melanoma cells.
- Open Access
- 20 March 2019
- Published by Springer Nature in Gastric Cancer
- Vol. 22 (5) , 920-931
Frequency of CDH1 germline variants and contribution of dietary habits in early age onset gastric cancer patients in Brazil
The contribution of CDH1 germline variants to gastric cancer burden among young adults is unknown in Brazil. We aimed to evaluate the frequency of CDH1 germline variants and the diet/lifestyle habits in early age onset gastric cancer (EOGC, ≤ 55 years old) patients.
- 20 March 2019
- Published by Springer Nature in Gastric Cancer
- Vol. 22 (5) , 920-931
Open AccessFrequency of CDH1 germline variants and contribution of dietary habits in early age onset gastric cancer patients in Brazil
The contribution of CDH1 germline variants to gastric cancer burden among young adults is unknown in Brazil. We aimed to evaluate the frequency of CDH1 germline variants and the diet/lifestyle habits in early age onset gastric cancer (EOGC, ≤ 55 years old) patients.
- Open Access
- 1 October 2018
- Published by Spandidos Publications in Molecular and Clinical Oncology
- Vol. 9 (4) , 377-388
Immunoexpression of claudins 4 and 7 among invasive breast carcinoma subtypes: A large diagnostic study using tissue microarray
Molecular phenotyping and tissue microarray (TMA) studies have identified distinct invasive breast carcinoma subtypes: Luminal A, luminal B, enriched with overexpressed human epidermal growth factor receptor 2 (HER-2) and triple-negative, i.e., negative for HER-2, as well as for estrogen and progesterone receptor (ER and PR, respectively) expression. These subtypes are useful in clinical management, since they bear distinct prognoses and predictive responses to targeted therapy. However, although molecular profiling provides important prognostic indicators, breast cancer risk stratification remains a challenge in triple-negative cases. What is referred to as claudin-low subtype was identified as a triple-negative subset that is associated with more aggressive tumor behavior and worse prognosis. However, the immunohistochemical expression of claudins has not yet been standardized. Our objective was to verify whether the immunoexpression of claudins 4 and 7 (the main claudins specifically expressed in human breast tissue) in TMA is associated with survival and prognosis in luminal A, HER-2 and triple-negative molecular subtypes. In this diagnostic study, we investigated ER/PR receptor status, HER-2, claudin 4 and 7 expression and stem cell CD44/24 profiles, and verified the association with prognosis and survival outcomes in 803 invasive breast carcinoma cases arranged in four TMAs. Among these, 503 (62.6%) were positive for claudin 4 and 369 (46.0%) for claudin 7. Claudin 4 exhibited the lowest expression in luminal A and triple-negative subtypes, and the highest frequency of expression in HER-2-enriched subtypes, whereas claudin 7 staining was not associated with any subtype. The stem cell phenotype was not associated with subgroups or claudins 4 and 7. Claudin immunoexpression profile was not able to distinguish between patients with better or worse prognosis, and it was not correlated to triple-negative cases. Therefore, it may be concluded that the immunoexpression of claudins 4 and 7, individually or within the usual immunohistochemical context (ER, PR and HER-2), does not provide additional prognostic information on breast cancer subtypes.
- 1 October 2018
- Published by Spandidos Publications in Molecular and Clinical Oncology
- Vol. 9 (4) , 377-388
Open AccessImmunoexpression of claudins 4 and 7 among invasive breast carcinoma subtypes: A large diagnostic study using tissue microarray
Molecular phenotyping and tissue microarray (TMA) studies have identified distinct invasive breast carcinoma subtypes: Luminal A, luminal B, enriched with overexpressed human epidermal growth factor receptor 2 (HER-2) and triple-negative, i.e., negative for HER-2, as well as for estrogen and progesterone receptor (ER and PR, respectively) expression. These subtypes are useful in clinical management, since they bear distinct prognoses and predictive responses to targeted therapy. However, although molecular profiling provides important prognostic indicators, breast cancer risk stratification remains a challenge in triple-negative cases. What is referred to as claudin-low subtype was identified as a triple-negative subset that is associated with more aggressive tumor behavior and worse prognosis. However, the immunohistochemical expression of claudins has not yet been standardized. Our objective was to verify whether the immunoexpression of claudins 4 and 7 (the main claudins specifically expressed in human breast tissue) in TMA is associated with survival and prognosis in luminal A, HER-2 and triple-negative molecular subtypes. In this diagnostic study, we investigated ER/PR receptor status, HER-2, claudin 4 and 7 expression and stem cell CD44/24 profiles, and verified the association with prognosis and survival outcomes in 803 invasive breast carcinoma cases arranged in four TMAs. Among these, 503 (62.6%) were positive for claudin 4 and 369 (46.0%) for claudin 7. Claudin 4 exhibited the lowest expression in luminal A and triple-negative subtypes, and the highest frequency of expression in HER-2-enriched subtypes, whereas claudin 7 staining was not associated with any subtype. The stem cell phenotype was not associated with subgroups or claudins 4 and 7. Claudin immunoexpression profile was not able to distinguish between patients with better or worse prognosis, and it was not correlated to triple-negative cases. Therefore, it may be concluded that the immunoexpression of claudins 4 and 7, individually or within the usual immunohistochemical context (ER, PR and HER-2), does not provide additional prognostic information on breast cancer subtypes.